#United States #UCB #Georgia #Biologics #Gwinnett County

UCB Unveils New Biologics Manufacturing Campus in Georgia

UCB, a global biopharmaceutical leader, recently celebrated the official dedication of its new biologics manufacturing campus in Gwinnett County, Georgia. This significant investment highlights UCB's commitment to advancing innovation and improving patient access to treatments for severe diseases.

The Dedication Ceremony

On October 9, 2026, the dedication ceremony gathered various stakeholders, including government officials from Georgia and the U.S. Department of Commerce, UCB executives, and community partners. The event underscored the collaborative efforts that led to establishing one of Georgia's largest life sciences manufacturing investments. Attendees rallied around the future site, which aims to propel the local economy and foster workforce development.

Attending the ceremony were notable figures, including Georgia Governor Brian Kemp and U.S. Department of Commerce Under Secretary Jeffrey Kessler. UCB's CEO, Jean-Christophe Tellier, articulated the company's focus on creating value for those suffering from severe conditions. He emphasized that this new manufacturing facility symbolizes a long-term investment in the community, enhancing UCB's ability to drive innovation within the life sciences sector.

A Symbolic Tribute

During the ceremony, the unveiling of the “Emmanuel Janssen Circle” took place, named after UCB’s founder. This tribute symbolizes the entrepreneurial spirit that has driven UCB's mission over the decades. Located at the entrance of the campus, the installation represents UCB's deep-rooted commitment to excellence in the biopharmaceutical industry.

UCB’s Vision for U.S. Manufacturing

In his remarks, Governor Kemp expressed pride in the partnership formed between UCB and Georgia, highlighting the state’s promising future as a center for life sciences. The county's conducive ecosystem and workforce skills have made it an ideal location for UCB's growth.

The biomanufacturing campus is set to occupy 79 acres within the Rowen innovation district. It will span approximately 460,000 square feet, integrating advanced technologies such as artificial intelligence and automation to streamline the production of complex biologic medicines.

Economic Impact and Job Creation

UCB's ambitious plans involve an investment of around $2 billion, projected to generate economic impacts exceeding $5 billion. This plant is expected to create approximately 330 high-skilled jobs and support over 1,000 construction jobs, further bolstering Georgia's economy. UCB aims to engage local universities and workforce development organizations to foster a talent pipeline tailored to meet industry demands.

The new facility emphasizes UCB’s mission to ensure long-term accessibility to innovative treatments. With a digital-first approach, the campus will support both the production of recently approved biologics and facilitate the development of future therapies, thus enhancing UCB's patient value chain from research through manufacturing and delivery.

Strengthening UCB's Presence in the U.S.

Since establishing its U.S. headquarters in Atlanta over 30 years ago, UCB has grown significantly. The new campus will augment its manufacturing capabilities and strengthen its role within the U.S. biopharmaceutical landscape.

As UCB embarks on this new chapter in Georgia, it reaffirms its commitment not only to its patients but also to creating a thriving life sciences ecosystem in the region. The dedication of the new campus illustrates UCB’s forward-thinking approach and dedication to advancing patient care through biopharmaceutical innovation.

In conclusion, UCB's new biologics manufacturing facility is more than just a construction project; it represents a firm commitment to the community and patients, promising a future with enhanced access to groundbreaking treatments and robust economic growth in Georgia.

• ---